|
FDA Rejects Watson Dispute Resolution Request on Vaginal Gel
Watson Pharmaceuticals was dealt a blow last week when the FDA denied its formal dispute resolution request (FDRR) seeking approval for its progesterone vaginal gel.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives